Figure 3.
Effect of tetracycline on Tet-FGF-2 and AS-VEGF/Tet-FGF-2 tumor growth. Nude mice were transplanted subcutaneously with 1 × 106 Tet-FGF-2 A4 cells (○, •) or AS-VEGF/Tet-FGF-2 C1 cells (▵, ▴). Animals were left untreated (•, ▴) or received 2 mg/ml of tetracycline in the drinking water throughout the whole experimental period starting 4 days before cell transplantation (○, ▵). Each point is the mean ± SE of five tumors. The results are representative of three independent experiments. Statistical analysis of tumor volumes by analysis of variance followed by Tukey-Kramer posthoc test showed a significant difference (P < 0.01) between the untreated Tet-FGF-2 group and all of the other groups (day 43, **) and between tetracycline-treated Tet-FGF-2 group and the two AS-VEGF/Tet-FGF-2 groups (day 43 and day 64, *). No significant difference was observed between untreated and tetracycline-treated AS-VEGF/Tet-FGF-2 groups at any time point.